PDCD1 and melanoma: Vibostolimab (MK-7684), a monoclonal antibody targeting TIGIT (NCT04165070, NCT04305054, NCT04305041, NCT02964013, NCT04303169, NCT05007106, NCT05005442, NCT05226598), is undergoing phase I and II clinical trials, used both as a monotherapy, or in combination with PD-1 inhibitors, and in chemotherapy in patients with metastatic solid tumors and melanoma.